No Data
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
Should Weakness in Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
At the end of the year, Jiangsu Hengrui Pharmaceuticals has made another achievement in business development, with an ADC new drug receiving a first payment of 75 million USD | Quick read of the announcement.
① This evening, Jiangsu Hengrui Pharmaceuticals announced that the overseas rights for the DLL3 ADC innovative drug SHR-4849 have been granted to USA's IDEAYA Biosciences, resulting in a payment of 75 million USD as an upfront fee; ② Jiangsu Hengrui Pharmaceuticals is accelerating its international development. Previously, Sun Piaoyang stated: going abroad is a path we must take, and how to do it steadily and successfully is a question we continue to explore.
Jiangsu Hengrui Pharmaceuticals (600276.SH): Signed a licensing agreement for the SHR-4849 project with IDEAYA Biosciences.
On December 29, Gu Longhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced an agreement with IDEAYA Biosciences, whereby the company granted IDEAYA Biosciences a paid license for the injectable new drug SHR-4849, which has independent intellectual property rights. SHR-4849 is an antibody-drug conjugate (ADC) targeting DLL3 developed by Hengrui with its own intellectual property.
Hengrui Medicine Gets Nod to Trial Prostate Cancer Drug
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
